Rebecca Sipione

Ms. Rebecca Sipione

University of Geneva, Geneva, Genève, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
SCSarah Ellen Carnemolla
Sarah Ellen Carnemolla
JHJulien Wen Hsieh
Julien Wen Hsieh
RSRebecca Sipione
Rebecca Sipione
BLBasile N. Landis
Basile N. Landis
FKFiona Kumfor
Fiona Kumfor
AMAurélie L. Manuel
Aurélie L. Manuel

Verified
Journal Article
Open access
PDF file
RSRebecca Sipione
Rebecca Sipione
NLNicolas Liaudet
Nicolas Liaudet
FRFrancis Rousset
Francis Rousset
BLBasile N. Landis
Basile N. Landis
JHJulien Wen Hsieh
Julien Wen Hsieh
PSPascal Senn
Pascal Senn
One of the most prevalent causes of olfactory loss includes traumatic brain injury with subsequent shearing of olfactory axons at the level of the cribriform plate (anterior skull base). Scar tissue at this level may prevent axonal regrowth toward the olfactory bulb. Currently, there is no cure for this debilitating and often permanent condition. One promising therapeutic concept is to implant a synthetic scaffold with growth factors through the cribriform plate/scar tissue to induce neuroregeneration. The first step toward this goal is to investigate the optimum conditions (growth factors, extracellular matrix proteins) to boost this regeneration. However, the lack of a specifically tailored in vitro model and an automated procedure for quantifying axonal length limits our ability to address this issue. The aim of this study is to create an automated quantification tool to measure axonal length and to determine the ideal growth factors and extracellular proteins to enhance axonal regrowth of olfactory sensory neurons in a mouse organotypic 2D model. We harvested olfactory epithelium (OE) of C57BL/6 mice and cultured them during 15 days on coverslips coated with various extracellular matrix proteins (Fibronectin, Collagen IV, Laminin, none) and different growth factors: fibroblast growth factor 2 (FGF2), brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), retinoic acid (RA), transforming growth factor β (TGFβ), and none. We measured the attachment rate on coverslips, the presence of cellular and axonal outgrowth, and finally, the total axonal length with a newly developed automated high-throughput quantification tool. Whereas the coatings did not influence attachment and neuronal outgrowth rates, the total axonal length was enhanced on fibronectin and collagen IV (p = 0.001). The optimum growth factor supplementation media to culture OE compared to the control condition were as follows: FGF2 alone and FGF2 from day 0 to 7 followed by FGF2 in combination with NGF from day 7 to 15 (p < 0.0001). The automated quantification tool to measure axonal length outperformed the standard Neuron J application by reducing the average analysis time from 22 to 3 min per specimen. In conclusion, robust regeneration of murine olfactory neurons in vitro can be induced, controlled, and efficiently measured using an automated quantification tool. These results will help advance the therapeutic concept closer toward preclinical studies.

1 August 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
JHJulien W. Hsieh
Julien W. Hsieh
DDDimitrios Daskalou
Dimitrios Daskalou
VDValentine Detroux
Valentine Detroux
RSRebecca Sipione
Rebecca Sipione
PSPascal Senn
Pascal Senn
BLBasile N. Landis
Basile N. Landis

5 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
FRFrancis Rousset
Francis Rousset
GSGiulia Schilardi
Giulia Schilardi
SSStéphanie Sgroi
Stéphanie Sgroi
GNGerman Nacher-Soler
German Nacher-Soler
RSRebecca Sipione
Rebecca Sipione
PSPascal Senn
Pascal Senn
Hearing loss affects over 460 million people worldwide and is a major socioeconomic burden. Both genetic and environmental factors (i.e., noise overexposure, ototoxic drug treatment and ageing), promote the irreversible degeneration of cochlear hair cells and associated auditory neurons, leading to sensorineural hearing loss. In contrast to birds, fish and amphibians, the mammalian inner ear is virtually unable to regenerate due to the limited stemness of auditory progenitors, and no causal treatment is able to prevent or reverse hearing loss. As of today, a main limitation for the development of otoprotective or otoregenerative therapies is the lack of efficient preclinical models compatible with high-throughput screening of drug candidates. Currently, the research field mainly relies on primary organotypic inner ear cultures, resulting in high variability, low throughput, high associated costs and ethical concerns. We previously identified and characterized the phoenix auditory neuroprogenitors (ANPGs) as highly proliferative progenitor cells isolated from the A/J mouse cochlea. In the present study, we aim at identifying the signaling pathways responsible for the intrinsic high stemness of phoenix ANPGs. A transcriptomic comparison of traditionally low-stemness ANPGs, isolated from C57Bl/6 and A/J mice at early passages, and high-stemness phoenix ANPGs was performed, allowing the identification of several differentially expressed pathways. Based on differentially regulated pathways, we developed a reprogramming protocol to induce high stemness in presenescent ANPGs (i.e., from C57Bl6 mouse). The pharmacological combination of the WNT agonist (CHIR99021) and TGFβ/Smad inhibitors (LDN193189 and SB431542) resulted in a dramatic increase in presenescent neurosphere growth, and the possibility to expand ANPGs is virtually limitless. As with the phoenix ANPGs, stemness-induced ANPGs could be frozen and thawed, enabling distribution to other laboratories. Importantly, even after 20 passages, stemness-induced ANPGs retained their ability to differentiate into electrophysiologically mature type I auditory neurons. Both stemness-induced and phoenix ANPGs resolve a main bottleneck in the field, allowing efficient, high-throughput, low-cost and 3R-compatible in vitro screening of otoprotective and otoregenerative drug candidates. This study may also add new perspectives to the field of inner ear regeneration.

1 November 2023 in Rhinology journal
Verified
Journal Article
Closed access
JHJ W Hsieh
J W Hsieh
VLV Lenoir
V Lenoir
RSRebecca Sipione
Rebecca Sipione
MHM Hugentobler
M Hugentobler
DDDimitrios Daskalou
Dimitrios Daskalou
BLBasile N. Landis
Basile N. Landis
Although most patients with post-traumatic olfactory dysfunction (PTOD) undergo MRI, there is no consensus about its diagnostic or prognostic value. The aims were: 1) to classify the extent of post-traumatic neurodegeneration; 2) to determine its relationship with chemosensory dysfunction (smell, taste, trigeminal); and 3) to establish whether MRI can predict olfactory improvement. We conducted a retrospective cohort study based on a series of 56 patients with PTOD. All patients underwent validated psychophysical tests of their smell, taste, and trigeminal functions, otorhinolaryngologic evaluation, and MRI. An experienced radiologist blinded to patient data evaluated 40 chemosensory-relevant brain regions according to a four-point scale (0=no lesion to 3=large lesion). Follow up data after 4 years (on average) were available in 46 patients. The cluster analysis showed 4 brain lesion patterns that differed in lesion localization and severity. They are associated with diagnostic categories: anosmia, hyposmia and normosmia. Two clusters were highly specific for anosmia (100% specificity) and could accurately predict this condition (100% positive predictive value). No clusters were associated with trigeminal or taste dysfunction. Regarding improvement, 72.7% of patients in the cluster with mild lesions experienced subjective and measurable olfactory improvement whereas this was only the case in 21.7-37.5% of patients with larger lesions. The odds of subjective smell improvement were 5.9 times higher in patients within the milder cluster compared to larger ones. The analysis of brain lesions in PTOD allows corroboration of smell test results and prediction of subjective and measurable improvement.

1 August 2024 in Otology & Neurotology
Verified
Journal Article
Open access
DDDimitrios Daskalou
Dimitrios Daskalou
JHJulien W. Hsieh
Julien W. Hsieh
MHMarianne Hugentobler
Marianne Hugentobler
SMSonia Macario
Sonia Macario
RSRebecca Sipione
Rebecca Sipione
BLBasile N. Landis
Basile N. Landis
Objective: To investigate the impact of cerebellopontine angle (CPA) masses on subjective and measured taste function. Study Design: Retrospective cross-sectional study. Setting: Tertiary referral center. Patients: Consecutive adult patients with untreated CPA masses. Interventions: Gustatory function was psychophysically measured with Taste Strips (range, 0–16) on both sides of the tongue. Subjective taste complaints were assessed using a questionnaire. Main Outcome Measures: Half-sided taste impairment (hemi-ageusia) was defined as side-to-side asymmetry ≥4 points with <9 points on the side of the CPA mass. We used the Koos classification for vestibular schwannomas (VS) and, in the case of facial nerve palsy, the House–Brackmann grading system. Results: We included 135 patients (mean [standard deviation (SD)] age, 55.3 ± 14.1 yr; 62 males). The most common CPA mass was VS (77%). Overall, the measured taste function was lower on the affected compared with the healthy side of the tongue (mean score, 9.8 ± 3.3 versus 11 ± 2.9; p < 0.0001). Looking for clinically relevant one-sided taste impairment revealed 18 (13.3%) patients with hemi-ageusia, but only 4 (30.8%) of those subjectively complained of taste dysfunction. Regarding VS, Koos IV masses presented the lowest score on the affected side (mean score, 7.5 ± 3.7). Six patients presented with facial palsy. Having facial palsy did not result in a lower Taste Strips score (p = 0.23). Conclusion: Before any CPA mass treatment, a measurable ipsilateral decrease in gustatory function is present in many patients. Most patients do not notice this preexisting taste impairment. From a medicolegal standpoint, this warrants consideration. To avoid postoperative claims regarding taste function, a preoperative assessment may be considered.